These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 7867438)

  • 1. [The pharmacokinetics of ciprofloxacin in patients with renal function of various degrees].
    Yu H; Wang HY; Sun ZM
    Zhonghua Nei Ke Za Zhi; 1994 Jul; 33(7):449-51. PubMed ID: 7867438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function.
    Gasser TC; Ebert SC; Graversen PH; Madsen PO
    Antimicrob Agents Chemother; 1987 May; 31(5):709-12. PubMed ID: 3300537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of the pharmacology of intravenously administered ciprofloxacin.
    Drusano GL
    Am J Med; 1987 Apr; 82(4A):339-45. PubMed ID: 3578325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
    Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
    Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and dosage regimen of ciprofloxacin following single intramuscular administration in Teddy goats.
    Iqbal Z; Javed I; Basit A; Jan I; Khan AA
    Pak J Pharm Sci; 2011 Jan; 24(1):69-74. PubMed ID: 21190922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of ciprofloxacin in liver cirrhosis.
    Ruhnke M; Trautmann M; Borner K; Hopfenmüller W
    Chemotherapy; 1990; 36(6):385-91. PubMed ID: 2292201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke.
    Strid S; Borgå O; Edenius C; Jostell KG; Odergren T; Weil A
    Eur J Clin Pharmacol; 2002 Sep; 58(6):409-15. PubMed ID: 12242600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite.
    Kirch W; Köhler H; Berggren G; Braun W
    Clin Nephrol; 1982 Aug; 18(2):88-94. PubMed ID: 7140021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD.
    Kowalsky SF; Echols M; Schwartz MT; Bailie GR; McCormick E
    Clin Nephrol; 1993 Jan; 39(1):53-8. PubMed ID: 8428409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
    Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
    J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose adjustment of ciprofloxacin in renal failure: reduce the dose or prolong the administration interval?
    Czock D; Rasche FM
    Eur J Med Res; 2005 Apr; 10(4):145-8. PubMed ID: 15946909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of renal function on recainam pharmacokinetics and pharmacodynamics.
    Cheng JW; Charland SL; Goldfarb S; Spinler SA
    Clin Pharmacol Ther; 1995 May; 57(5):492-8. PubMed ID: 7768071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.
    Sobue S; Tan K; Layton G; Leclerc V; Weil A
    Br J Clin Pharmacol; 2004 Jun; 57(6):773-84. PubMed ID: 15151523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elimination of ciprofloxacin and three major metabolites and consequences of reduced renal function.
    Bergan T; Thorsteinsson SB; Rohwedder R; Scholl H
    Chemotherapy; 1989; 35(6):393-405. PubMed ID: 2612228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
    Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function.
    Drusano GL; Weir M; Forrest A; Plaisance K; Emm T; Standiford HC
    Antimicrob Agents Chemother; 1987 Jun; 31(6):860-4. PubMed ID: 3619418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans.
    Jaehde U; Sörgel F; Reiter A; Sigl G; Naber KG; Schunack W
    Clin Pharmacol Ther; 1995 Nov; 58(5):532-41. PubMed ID: 7586947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects.
    Shah A; Lettieri J; Blum R; Millikin S; Sica D; Heller AH
    J Antimicrob Chemother; 1996 Jul; 38(1):103-16. PubMed ID: 8858462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
    Zhou XJ; Swan S; Smith WB; Marbury TC; Dubuc-Patrick G; Chao GC; Brown NA
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4231-5. PubMed ID: 17875994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.